International: +1-347-960-6455
Hereditary Angioedema (HAE) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

According to a new research report Hereditary Angioedema (HAE) Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, HAE therapeutics currently exhibits a proliferating pipeline with 20+ therapeutic candidates.

HAE Therapeutics Pipeline Insights

HAE is a genetic disease that results in swelling under the skin, lining of guts and lungs. Symptoms of the disease usually occur in childhood, and get aggravated in teenage. The symptoms include bouts of swelling and itching, which are usual characteristics of allergy infections. The swelling occurs in various parts of the body such as throat, mouth, hands, feet, face, genitals, belly, and other parts of a body. The disease can be trigger due to stress, anxiety, injury, surgery, flu, heart or blood pressure medications. Genetic mutation is another major reason for the occurrence of HAE.

HAE can be diagnosed on the basis of family history, laboratory tests, and physical examinations. Various treatment options are available for the disease, such as Berinert (CSL Behring), Kalbitor, Takhzyro, Firazyr, and Ecallantide developed by Shire plc and Dyax Corp.

Insights into Pipeline Segments

According to the research, many drugs being developed for HAE are administered intravenously (IV). It has been found that IV route of medication is the most effective way in terms of rapid onset of action, and therefore, is more helpful in pain and swelling related to HAE.

Positive Clinical Trial Results are Expected to Drive HAE Therapeutics Pipeline

There are several companies that are involved in developing therapeutics for HAE have shown positive topline clinical results in various phases of drug development. For instance, BioCryst Pharmaceuticals Incorporated announced positive phase II result in February 2019 for BCX7353, which is designed to be administered orally for HAE.

Strategic Developments Play a Pivotal Role in HAE Therapeutics Development

There are several acquisitions and partnerships reported in the wake of technological developments for HAE therapeutics. For instance, in 2016, Shire plc merged with Baxalta Incorporated for expansion of its portfolio of rare diseases including HAE. Moreover, Takeda Pharmaceutical Company Limited acquired Shire plc in January 2019 in order to expand its geographic footprint.

Browse report overview with detailed TOC on "Hereditary Angioedema (HAE) Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments" at:

Pharming Group N.V., Alnylam Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring, Ionis Pharmaceuticals Inc., and Takeda Pharmaceutical Company Limited are some of the major players involved in the development of therapeutics for HAE.

HAE Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of HAE. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the HAE therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to HAE.